MIR215

Summary

MIR215 (microRNA 215, HGNC:31592) is a microRNA gene on chromosome 1q41.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406997 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31592
Approved symbol	MIR215
Name	microRNA 215
Location	1q41
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-215
Ensembl gene	ENSG00000207590
Ensembl biotype	miRNA
OMIM	610943
Entrez	406997
RNAcentral	URS00000F31F4 — miRNA, 110 nt, 2 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384858

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384858 — 1 exons

Exon	Start	End
ENSE00001499865	220117853	220117962

Expression profiles

Bgee: expression breadth broad, 96 present calls, max score 83.49.

Top tissues by expression

96 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	83.49	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	83.36	gold quality
duodenum	UBERON:0002114	81.11	gold quality
blood	UBERON:0000178	78.47	gold quality
monocyte	CL:0000576	78.45	gold quality
corpus callosum	UBERON:0002336	77.41	gold quality
endometrium	UBERON:0001295	76.87	gold quality
fundus of stomach	UBERON:0001160	75.55	gold quality
liver	UBERON:0002107	75.21	gold quality
stomach	UBERON:0000945	74.77	gold quality
bone marrow	UBERON:0002371	73.98	gold quality
islet of Langerhans	UBERON:0000006	73.97	gold quality
lymph node	UBERON:0000029	73.75	gold quality
gastrocnemius	UBERON:0001388	73.72	gold quality
muscle of leg	UBERON:0001383	73.32	gold quality
kidney	UBERON:0002113	72.84	gold quality
adrenal gland	UBERON:0002369	72.69	gold quality
small intestine	UBERON:0002108	72.61	gold quality
apex of heart	UBERON:0002098	72.59	gold quality
small intestine Peyer’s patch	UBERON:0003454	71.95	gold quality
intestine	UBERON:0000160	71.78	gold quality
heart	UBERON:0000948	71.50	gold quality
mucosa of transverse colon	UBERON:0004991	71.47	gold quality
body of pancreas	UBERON:0001150	71.09	gold quality
calcaneal tendon	UBERON:0003701	70.51	gold quality
right ovary	UBERON:0002118	70.32	gold quality
urinary bladder	UBERON:0001255	70.04	gold quality
right lobe of liver	UBERON:0001114	69.99	gold quality
tibial artery	UBERON:0007610	69.92	gold quality
body of stomach	UBERON:0001161	69.90	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.06

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Results showing a role for miR-192/215 in cell proliferation combined with recent observations that these miRNAs are underexpressed in primary cancers support the idea that miR-192 and miR-215 function as tumor suppressors. (PMID:19074876)
• miR-215, through the suppression of DTL expression, induces a decreased cell proliferation leading to an increase in chemoresistance (PMID:20433742)
• miR-192 and miR-215 target thymidylate synthase expression in colorectal cancer cell lines. (PMID:20647341)
• in gastric cancer, both microRNA-192 and -215 are overexpressed in vivo and exert cell growth and migration-promoting effects in vitro. (PMID:21119604)
• Loss of miR-215 is associated with colon cancer. (PMID:21752725)
• Overexpression of miR-215 decreased cellular migration and invasion in an RCC cell line model. (PMID:22033272)
• Down-regulation of MIRN215 is associated with gastric carcinoma. (PMID:22205577)
• miR-378, miR-375, miR-422a and miR-215 play an important role in the colorectal cancer as tumour suppressors (PMID:22469014)
• MicroRNA-215 functions as a predictive marker for relapse following radical surgery of colorectal cancer. (PMID:23532818)
• we showed that miR-192, miR-194 and miR-215 have tumor suppressor effects on RCC by reducing the cellular migration and invasion abilities. (PMID:23715501)
• miR-215 targets retinoblastoma tumor-suppressor gene 1 (RB1) through its 3’-UTR in gastric cancer cells. (PMID:23981575)
• It was concluded that the expression level of miR-215 is associated with cervical tumor progression and worse survival rate, suggesting that it may serve as a potential prognostic marker to identify patients at higher risk of recurrence. (PMID:24710934)
• frequently up-regulated miR-215/192 in gastric cancer may participate in gastric cancer progression (PMID:24981590)
• the expression of miR-143 and miR-215 in serum were significantly up-regulated in patients with chronic hepatitis and Hepatocellular carcinoma (PMID:24993656)
• High MIR215 expression is associated with atypical coronary artery disease. (PMID:25198728)
• There is a high expression of miR-215 in breast cancer, making it a useful prognostic marker. (PMID:25270284)
• MicroRNA-215 has a role in regulating fibroblast function in the ocular disease pterygium (PMID:25565137)
• miR-215 is a link between CDX1 expression and BMI1 repression that governs differentiation in colorectal cancer (PMID:25775580)
• Aberrant expression of MiR-215/192 inhibits cell migration and cell proliferation via nidogen-1. (PMID:25857602)
• miR-215 overexpression distinguishes ampullary carcinomas from pancreatic carcinomas. (PMID:26063036)
• MicroRNA-215 is upregulated by treatment with Adriamycin and leads to the chemoresistance of hepatocellular carcinoma cells and tissues (PMID:26135967)
• analysis of miR-215 mediated targets and pathways in human colorectal neoplasms (PMID:26287603)
• Data show that microRNA miR-215 activates beta-catenin pathways by decreasing catenin beta interacting protein 1 (CTNNBIP1)expression in gliomas. (PMID:26317904)
• we identified miR-215 as a potential tumor suppressor in patients with EOC downregulating expression of the oncogenic regulator XIAP (PMID:26676658)
• High expression of miR-215 is associated with malignant progression of gastric cancer. (PMID:26716895)
• reveal a direct role of hypoxia-inducible factor in regulating miRNA biogenesis and consequently activating the miR-215-KDM1B-mediated signaling required for glioma-initiating cells adaptation to hypoxia (PMID:26766590)
• reduced microRNA-215 expression is a common event and is associated with poor clinical outcome in acute myeloid leukemia (PMID:26802165)
• miR-192 levels are significantly higher than the miR-194 and miR-215 levels in urine extracellular vesicles and all three miRNAs are significantly increased in microalbuminuria compared with normoalbuminuria in early-stage diabetic nephropathy (PMID:26942205)
• miR-215 is downregulated in colon cancer and it suppresses colon cancer cell proliferation, migration and invasion by directly targeting YY1 (PMID:27663660)
• miR-215 acts in concert with the host gene IARS2 to affect neuron migration and proliferation through the target gene SIGLEC-8. (PMID:28006787)
• miR-215-5p up-regulation and PCDH9 down-regulation occurs in glioma samples. miR-215-5p could inhibit the mRNA and protein levels of PCDH9 in glioma cell lines by targeting its promoter and 3’ UTR at the same time. (PMID:28055966)
• miR-215 promotes cell migration and invasion of gastric cancer by targeting FOXO1. (PMID:28485164)
• RB1 was identified as a direct and functional target of miR-215. RB1 is generally down-regulated in glioma tissues and its expression inversely correlated with miR-215, which is up-regulated in high-grade glioma tissues, and its expression was negatively correlated with miR-215. (PMID:28573541)
• miR-215 promoted cell migration and invasion of gastric cancer by directly targeting RB1. (PMID:28689850)
• TP53-miR-215-PCAT-1-CRKL axis might represent an important regulatory pathway in hepatocellular carcinoma. (PMID:28887306)
• Study shows that miR-215 regulates the Act1/IL-17RA pathway and represses the expression of Act1 protein in oxygen glucose deprivation/reperfusion-treated N2a cells and an middle cerebral artery occlusion mouse model of ischemic stroke. (PMID:29080697)
• SMG-1 is a target of the oncomiRs, miR-192 and -215, and that its downregulation is associated with tumor size and serosal invasion of gastric cancer (GC). SMG-1 appears to mediate at least some of the oncogenic function of miR-192 and -215 by participating in epithelial-mesenchymal transition, triggered by activation of the Wnt pathway in GC. (PMID:29239144)
• miR-215 facilitated HCV replication via inactivation of the NF-kappaB pathway by inhibiting TRIM22, providing a novel potential target for HCV infection. (PMID:29749134)
• expression analysis of miRNAs from serum in osteosarcoma patients revealed differential expression of miR-215-5p and miR-642a-5p (PMID:29907935)
• Data demonstrated an oncogenic role of lncRNA FTX in CRC tumorigenesis and progression via interaction with miR-215 and vimentin. (PMID:29925853)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.